{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:15:13Z","timestamp":1788369313552,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clinthera.2024.03.012","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T21:30:48Z","timestamp":1716413448000},"page":"752-758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets"],"prefix":"10.1016","volume":"46","author":[{"given":"Samaneh","family":"Alaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Shiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Marroum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.03.012_bib0001","unstructured":"Venclexta (venetoclax) [package insert]. North Chicago, IL; AbbVie, Inc.; 2016. Revised 6\/2022."},{"key":"10.1016\/j.clinthera.2024.03.012_bib0002","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40261-022-01172-4","article-title":"Bioavailability evaluation of venetoclax lower-strength tablets and oral powder formulations to establish interchangeability with the 100 mg tablet","volume":"42","author":"Badawi","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0003","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0004","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0005","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/CAD.0000000000000522","article-title":"Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia","volume":"28","author":"Salem","year":"2017","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/dmd.113.055053","article-title":"The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199","volume":"42","author":"Choo","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0007","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.xphs.2017.09.027","article-title":"Mechanistic physiologically based pharmacokinetic modeling of the dissolution and food effect of a biopharmaceutics classification system IV compound-the venetoclax story","volume":"107","author":"Emami Riedmaier","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0008","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02493524","article-title":"Prevalence of swallowing complaints and clinical findings among 50-79-year-old men and women in an urban population","volume":"6","author":"Lindgren","year":"1991","journal-title":"Dysphagia"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0009","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.3390\/ijms22137033","article-title":"Molecular and neural mechanism of dysphagia due to cancer","volume":"22","author":"Okuni","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00280-022-04460-0","article-title":"Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia","volume":"90","author":"Sato","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0011","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00277-022-04871-2","article-title":"Increased blood levels of venetoclax due to intake of crushed venetoclax tablets","volume":"101","author":"Anzai","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00277-022-05014-3","article-title":"Impact of tablet crushing on the dissolution of venetoclax","volume":"102","author":"Yasu","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0013","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/ajhp\/zxaa412","article-title":"To crush or not to crush: a brief review of novel tablets and capsules prepared from nanocrystal and amorphous solid dispersion technologies","volume":"78","author":"Uttaro","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0014","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0015","unstructured":"AbbVie Inc. Venclexta (venetoclax) [package insert]. U.S. Food and Drug Adminstration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208573s023lbl.pdf. Accessed February 2024."},{"key":"10.1016\/j.clinthera.2024.03.012_bib0016","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/00498254.2017.1381779","article-title":"Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin","volume":"48","author":"Chiney","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0017","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jcph.741","article-title":"Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor","volume":"56","author":"Salem","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0018","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0019","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-016-0485-9","article-title":"Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers","volume":"37","author":"Salem","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0020","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5","year":"2009"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0021","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40266-023-01056-y","article-title":"Crushed tablet administration for patients with dysphagia and enteral feeding: challenges and considerations","volume":"40","author":"Blaszczyk","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0022","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijpharm.2013.08.061","article-title":"MODRIC - manipulation of drugs in children","volume":"457","author":"Richey","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121532","article-title":"Moisture sorption by polymeric excipients commonly used in amorphous solid dispersion and its effect on glass transition temperature: I. Polyvinylpyrrolidone and related copolymers","volume":"616","author":"Patel","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118884","article-title":"The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics","volume":"573","author":"Pas","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1208\/s12249-023-02622-8","article-title":"Effects of additives on the physical stability and dissolution of polymeric amorphous solid dispersions: a review","volume":"24","author":"Li","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0026","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpdd.123","article-title":"Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube","volume":"3","author":"Moore","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0027","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cpdd.1169","article-title":"Pharmacokinetics and safety of vibegron 75 mg administered as an intact or crushed tablet in healthy adults","volume":"11","author":"King","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0028","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/11319320-000000000-00000","article-title":"Multiple peaking phenomena in pharmacokinetic disposition","volume":"49","author":"Davies","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0029","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.addr.2005.07.001","article-title":"The basics and underlying mechanisms of mucoadhesion","volume":"57","author":"Smart","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12951-022-01539-x","article-title":"Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems","volume":"20","author":"Subramanian","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0031","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jcph.858","article-title":"Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model","volume":"57","author":"Freise","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0032","unstructured":"EMA Assessment Report: Venclyxto. Accessed October 2023 https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/venclyxto-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.clinthera.2024.03.012_bib0033","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/pharmaceutics9040041","article-title":"Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models","volume":"9","author":"Lin","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0034","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2017.01.014","article-title":"BCS class IV drugs: highly notorious candidates for formulation development","volume":"248","author":"Ghadi","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0035","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.addr.2011.05.019","article-title":"Intestinal lymphatic transport for drug delivery","volume":"63","author":"Yanez","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0036","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0168-3659(02)00418-2","article-title":"A computational model for particle size influence on drug absorption during controlled-release colonic delivery","volume":"86","author":"Waterman","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0037","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/hon.2646","article-title":"Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis","volume":"37","author":"Agarwal","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0038","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40262-016-0453-9","article-title":"Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"56","author":"Freise","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0039","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/10428194.2019.1657575","article-title":"Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study","volume":"61","author":"Deng","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2024.03.012_bib0040","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/jcph.2248","article-title":"Pooled population pharmacokinetic analyses of venetoclax in patients across indications and healthy subjects from phase 1, 2, and 3 clinical trials","volume":"63","author":"Gong","year":"2023","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T02:50:32Z","timestamp":1730343032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0149291824000808"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.03.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}